GlassScriptPhysician profile
April M Ferguson
NPI 1811167588
$7,524.82
in general payments reported to CMS, 2019-2025
29 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,158 · 2021: $1,622 · 2022: $1,475 · 2023: $1,716 · 2024: $1,415 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,258.95 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,366.84 | 2020-2024 | Cabenuva, Dovato, Apretude |
| Paratek Pharmaceuticals, INC. | $1,093.51 | 2020-2025 | Nuzyra |
| Gilead Sciences, INC. | $1,036.60 | 2020-2024 | Veklury |
| Merck Sharp & Dohme LLC | $743.10 | 2020-2025 | Dificid, Pifeltro, Delstrigo |
| Insmed, INC. | $523.85 | 2020-2024 | Arikayce |
| Janssen Biotech, INC. | $408.27 | 2020-2023 | Symtuza |
| Theratechnologies INC. | $380.26 | 2020-2025 | Egrifta, Trogarzo |
| Astellas Pharma US INC | $305.60 | 2021-2024 | Cresemba |
| Melinta Therapeutics, LLC | $302.38 | 2020-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Shionogi INC | $244.25 | 2022-2025 | Fetroja |
| Napo Pharmaceuticals INC | $161.98 | 2020-2023 | Mytesi |
| Amarin Pharma, INC. | $156.03 | 2020-2022 | |
| Emd Serono, INC. | $126.47 | 2020-2023 | Serostim |
| Abbvie INC. | $125.13 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $120.19 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $63.67 | 2021-2022 | |
| Allergan, INC. | $61.20 | 2020 | |
| Pfizer INC. | $55.08 | 2023-2024 | |
| La Jolla Pharmaceutical Company | $49.40 | 2024 | Xacduro |
| Smith+Nephew, INC. | $48.69 | 2023-2024 | Collagenase Santyl, Iodosorb Ointment 40g USA, Regranex |
| Vyera Pharmaceuticals, LLC | $25.37 | 2020 | |
| Janssen Pharmaceuticals, INC | $23.25 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.30 | 2022 | |
| Nestle Healthcare Nutrition INC. | $19.93 | 2023 | |
| Philips North America LLC | $15.12 | 2023 | |
| Ferring Pharmaceuticals INC. | $13.55 | 2024 | Rebyota |
| Tetraphase Pharmaceuticals, INC. | $12.63 | 2020 | |
| Baxter Healthcare | $11.98 | 2022 | |
| Kerecis Limited | $10.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.